Constellation joins the mega-round club with $100M raise and plans to pursue cancer studies
After keeping a fairly low profile for the past few years, Constellation Pharmaceuticals is stepping into the spotlight this morning, joining the megaround club in biotech with a broadened syndicate of crossover investors that fits the profile for companies grooming themselves for an IPO.
Adding in a $48 million round the company brought in at the end of 2016 — but didn’t spotlight — along with a $100 million round today, CEO Jigar Raythatha tells me that the company has now raised a total of $280 million since launching 10 years ago. And the story the company is telling now centers considerably on a pair of early-stage cancer studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.